AlbertoEspayMDMSc

Movement Disorder

Professor of Neurology Director and Endowed Chair, James J. and Joan A. Gardner Center for Parkinson’s Disease and Movement Disorders University of Cincinnati

Join to view full profile

Dr. Espay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Espay's full profile

Already have an account?

Office
222 Piedmont Avenue
Ste. 3100
Cincinnati, OH 45219
Phone+1 513-475-8730

Fax+1 513-475-8033

Summary

Dr. Alberto Espay is Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson’s disease at the University of Cincinnati. He has published over 300 peer-reviewed research articles and 8 books, including Common Movement Disorders Pitfalls, which received the Highly Commended BMA Medical Book Award in 2013 and Brain Fables, the Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer them, coauthored with Parkinson patient and advocate Benjamin Stecher, selected by the Association of American Publishers for the PROSE Award honoring the best scholarly work in Neuroscience published in 2020. He has served as Chair of the Movement Disorders Section of the American Academy of Neurology, Associate Editor of the Movement Disorders journal, and on the Executive Committee of the Parkinson Study Group. Among other honors, he has received the Cincinnati Business Courier’s Health Care Hero award, the Spanish Society of Neurology’s Cotzias award, and honorary membership in the Mexican Academy of Neurology. He currently serves as President-Elect of the Pan-American Section of the International Parkinson and Movement Disorders Society. With colleagues at the University of Cincinnati, he recently launched the first biomarker study of aging (CCBPstudy.com), designed to match people with neurodegenerative disorders to available therapies from which they are most biologically suitable to benefit, regardless of their clinical diagnoses.

Education & Training

University of TorontoM.Sc., Clinical Epidemiology and Health Care Research, 2003 - 2005
Indiana University School of MedicineResidency, Neurology, 1998 - 2001
Ascension St Vincent Hospital IndianapolisInternship, Transitional Year, 1997 - 1998
Central University of VenezuelaClass of 1994
Liceo de AplicacionB.S., 1987

Certifications & Licensure

OH State Medical License 2005 - 2027
NY State Medical License 2002 - 2005
NM State Medical License 1996 - 1996
American Board of Psychiatry and Neurology Neurology
National Board of Physicians and Surgeons Neurology

Awards, Honors, & Recognition

Top Doctor Cincinnati Magazine, 2014
Fellow American Academy of Neurology (FAAN), 2013
Fellow American Neurological Association (FANA), 2013
“Highly Commended” Neurology book, Medical Book Awards, for Common Movement Disorders Pitfalls: Case-Based Learning (Cambridge University Press, 2012) BMA, 2013
Best Abstract Award, (for Placebo effect in PD) Parkinson Study Group (PSG) Symposium, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Patients’ Choice Award 2011
Compassionate Doctor Award PatientsChoice.org, 2011
Tri-State’s Forty Under 40 Cincinnati Business Courier, 2010
Career Development Award Dystonia Coalition, 2010
Best Doctors in America 2009-2014
Honorary Member (Folio 039) Mexican Academy of Neurology, 2008
Physician Recognition Award with Commendation in Continuing Medical Education American Medical Association, 2008
Dean’s Scholar in Clinical Research Award Center for Clinical and Translational Science and Training, University of Cincinnati, 2006-2008
Best Oral Presentation Clinical Studies Resource Centre Clinical Research Half-Day, Toronto Western Hospital, University Health Network, Toronto, 2005
Alexander Treloar Ross Award Honorable Mention. Most outstanding paper presented by a Neurology Resident during the year 2000-2001. 2001
Join now to see all

Clinical Trials

Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease Start of enrollment: 2007 May 01
Terminated
Phase 4
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Start of enrollment: 2007 Dec 01
Completed
Phase 4
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Completed
Phase 2
The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias Start of enrollment: 2011 Jan 01
Completed
Parkinstep: Automated PD Gait and Balance Assessment for Optimizing DBS Start of enrollment: 2014 Feb 01
Completed
Treating Bacterial Overgrowth in Parkinson's Disease Start of enrollment: 2015 Dec 01
Completed
Phase 2, Phase 3
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Start of enrollment: 2016 Mar 01
Unknown status
Phase 3
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Start of enrollment: 2016 Jul 01
Unknown status
Phase 3
OnabotulinumtoxinA in the Management of Psychogenic Dystonia Start of enrollment: 2016 Jan 15
Completed
Phase 4
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Start of enrollment: 2019 Sep 30
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

4 citations
SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF Resulting in Drastic Soluble Protein Depletion.
Wanda Christ, Sebastian Kapell, Michal J Sobkowiak, Georgios Mermelekas, Björn Evertsson
ACS Chemical Neuroscience. 2024-11-20
Tremor Is Highly Responsive to Levodopa in Advanced Parkinson's Disease.
Bart E K S Swinnen, Henrieke L Frequin, Yarit Wiggerts, Alberto J Espay, Martijn Beudel
Movement Disorders Clinical Practice. 2024-11-09
Genetic Risk Factors in Isolated Dystonia Escape Genome-Wide Association Studies.
Björn-Hergen Laabs, Katja Lohmann, Eva-Juliane Vollstedt, Tobias Reinberger, Lisa-Marie Nuxoll
Movement Disorders. 2024-11-01

Journal Articles

Levodopa‐Induced Dyskinesia in Parkinson Disease: Current and Evolving Concepts
Aristide Merola, Alberto J Espay, Annals of Neurology
Impaired Emotion Processing in Functional (Psychogenic) Tremor: A Functional Magnetic Resonance Imaging Study
Thomas Maloney, Alberto J Espay, Jerzy P Szaflarski, ScienceDirect
Double-Blind, Double-Dummy, Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Ohtman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Anton..., Lancet Neurol, 12/19/2013
Psychogenic Movement Disorders Continuum (Minneap Minn)
Morgante F, Edwards MJ, Espay AJ, Movement Disorders, 10/1/2013
Myoclonus Continuum (Minneap Minn)
Espay AJ, Chen R, Movement Disorders, 10/1/2013
Commentary for “Cognitive impairment and PD patients’ capacity to consent to research” (Neurology 2013;81(9):801-7)
Espay AJ, Parkinson’s Disease Monitor & Commentary, 1/1/2013
Commentary for “Chediak-Higashi Syndrome Presenting as Young-Onset Levodopa-Responsive Parkinsonism”
Espay AJ, Mov Disord, 1/1/2013
Surgical Treatment of Parkinson's Disease: Past, Present, and Future
Duker AP, Espay AJ, Neurol Clin, 1/1/2013
Nosography of the “essential”: Volitional Palatal tremor
Biller J, Espay AJ, Neurology, 1/1/2013
Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics
Cholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu S-C, Edwards KL, Montine TJ, Leverenz JB, J Park Dis, 1/1/2013
Dilated Virchow-Robin spaces and parkinsonism
Mehta SH, Nichols FT, Espay AJ, Duker AP, Morgan JC, Sethi KD, Mov Disord, 1/1/2013
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 ...
Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S, on behalf of the IPX066 ADVANCE-PD investigators, Lancet Neurol, 1/1/2013
Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s disease Open-Label Study: Interim Results
Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA, Parkisonism Relat Disord, 1/1/2013
Long-duration Parkinson's Disease: Role of Lateralization of Motor Features
Munhoz RP, Espay AJ, Morgante F, Li J-Y, Teive HA, Dunn E, Gallin E, Litvan I, Park Related Disord, 1/1/2013
Atypical motor and behavioral presentations of Alzheimer’s disease: a case-based approach
Duker AP, Espay AJ, Wszolek ZK, Rademakers R, Dickson DW, Kelley BJ, Neurologist, 9/1/2012
Psychogenic facial movement disorders: clinical features and associated conditions
Fasano A, Valadas A, Bhatia KP, Prashanth LK, Lang AE, Munhoz RP, Morgante F, Tarsy D, Duker AP, Girlanda P, Bentivoglio AR, Espay AJ, Mov Disord, 1/1/2012
The six gaps in the search of neuroprotection for Parkinson’s disease
Espay AJ, Fasano A, Morgante F, Expert Rev Neurother, 1/1/2012
Finding gaps and building bridges in movement disorders
Fasano A, Espay AJ, Morgante F, Expert Rev Neurother, 1/1/2012
Commentary for “Diagnosis of Parkinson’s disease based on disease-specific autoantibody profiles in human sera” (PLoS One 2012;7:e32383)
Espay AJ, Parkinson’s Disease Monitor & Commentary, 1/1/2012
Commentary for "Opsoclonus myoclonus syndrome associated with GQ1b antibodies"
Espay AJ, Mov Disord, 1/1/2012
Creation of an open-access, mutation-defined fibroblast resource for neurological disease research
Wray S, Self M; NINDS Parkinson's Disease iPSC Consortium; NINDS Huntington's Disease iPSC Consortium; NINDS ALS iPSC Consortium, Lewis PA, Taanman JW, Ryan NS, Mahone..., PLoS One, 1/1/2012
Mirror movements in movement disorders
Cox BC, Cincotta M, Espay AJ, Tremor Other Hyperkinet Mov (NY), 1/1/2012
Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson’s disease
Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, Revilla FJ, Collier TJ, Mov Disord, 1/1/2012
Diagnostic agreement in patients with psychogenic movement disorders
Morgante F, Edwards MJ, Espay AJ, Fasano A, Mir P, Martino D, Mov Disord, 1/1/2012
"On” state freezing of gait in Parkinson’s disease: A paradoxical levodopa-induced complication
Espay AJ, Fasano A, van Nuenen BFL, Payne M, Snijders AH, Bloem BR, Neurology, 1/1/2012
Join now to see all

Press Mentions

Alzheimer’s Treatment Plot Twist: When (Healthy) Amyloid Goes up, Cognitive Decline Slows DownNovember 26th, 2024
Alzheimer's Data WithdrawnNovember 11th, 2024
Ozempic May Be Linked to Lower Risk of Alzheimer’s in People with Type 2 DiabetesOctober 24th, 2024
Join now to see all